Q.Name a microbe used for statin production. How do statins lower blood cholesterol level?

Statins are produced by the yeast Monascus purpureus, which has been used commercially for this purpose. These compounds belong to a group of blood-cholesterol-lowering agents that work by a very specific mechanism inside our body.

Statins act as competitive inhibitors of the enzyme HMG-CoA reductase. This enzyme plays a central role in cholesterol synthesis in the liver — it catalyzes an early and rate-limiting step in the pathway that produces cholesterol. By blocking this enzyme, statins effectively slow down the liver's ability to manufacture cholesterol from scratch. …

The discovery that certain microbes produce compounds capable of regulating human cholesterol was a landmark in medical biotechnology. Among the fungi exploited for this purpose, Monascus purpureus stands out as a commercially significant producer of statins. This yeast has been used for centuries in Asian food fermentation (notably in red yeast rice), but its pharmaceutical potential was recognized only when scientists isolated the cholesterol-lowering agents it secretes during fermentation.

Statins are a class of drugs that have revolutionized the treatment of hypercholesterolemia—dangerously high levels of cholesterol in the blood. The mechanism by which they work is elegantly simple and rooted in blocking a single, critical step in the body's cholesterol manufacturing process.

How Statins Lower Blood Cholesterol

Cholesterol synthesis in the human body occurs primarily in the liver. The pathway involves multiple enzymatic steps, but one enzyme acts as the rate-limiting gatekeeper: HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase). This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and essential step in the production of cholesterol.

Statins are competitive inhibitors of HMG-CoA reductase. Their molecular structure closely resembles that of HMG-CoA, the enzyme's natural substrate. When a statin molecule enters a liver cell, it binds to the active site of HMG-CoA reductase, effectively blocking the real substrate from accessing the enzyme. Because the enzyme is occupied by the statin and cannot process HMG-CoA into mevalonate, the entire cholesterol synthesis pathway downstream is slowed or halted.

A different angle: reason from the cholesterol-synthesis pathway itself, instead of starting from the microbe.

The liver builds cholesterol through a multi-step pathway whose earliest committed, rate-limiting step is controlled by one enzyme: HMG-CoA reductase. Any molecule that blocks that single enzyme throttles the whole downstream pathway at its narrowest point, which is a far more efficient lever than trying to block cholesterol at a dozen later steps. …